A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336

被引:1
|
作者
Carroll, F. Ivy [1 ]
Kosten, Thomas R. [2 ]
Buda, Jeffrey J. [1 ]
Wang, Laurene [3 ]
Walters, Bradford B. [1 ]
机构
[1] RTI Int, Res Triangle Pk, NC 27709 USA
[2] Baylor Coll Med, Psychiat Neurosci Pharmacol & Immunol & Pathol, Houston, TX 77030 USA
[3] INDApharma, Chapel Hill, NC USA
来源
关键词
RTI-336; dopamine transporter inhibitor; Clinical Trials; cocaine dependence; addiction and addiction behaviors; pharmacokinetics and drug metabolism (PDM); safety; tolerability; COCAINE USE DISORDER; DOPAMINE TRANSPORTER; NONHUMAN-PRIMATES; SQUIRREL-MONKEYS; RHESUS-MONKEYS; ABUSE; ANALOGS; DRUGS; PHARMACOTHERAPY; INHIBITORS;
D O I
10.3389/fphar.2018.00712
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Preclinical and clinical data suggest that a compound which binds potently to and inhibits the dopamine transporter, but with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity, could be a useful adjunct in the treatment of cocaine dependence. Methods: We assessed the safety, tolerability, and pharmacokinetics (PK) of oral single doses (0.3, 1, 3, 6, 12, and 20 mg) of such an analog, RTI-336, in a randomized, double-blind, and placebo-controlled trial in healthy adult males. Pre-dose and post-dose safety assessments included physical examinations (including neurological examination); orthostatic vital signs; 6-lead continuous electrocardiogram (ECG) telemetry monitoring pre-dose to 8 h post-dose; 12-lead ECGs; clinical chemistry, hematology, and urinalysis; mini mental status examinations; and adverse events. RTI-336 PK was assessed in plasma and urine. Results: 22 participants were enrolled. RTI-336 was well-tolerated up to the maximum evaluated dose of 20 mg. PK analyses demonstrated good absorption with peak plasma maximum concentrations (C-max) occurring around 4 h post-dose and consistent half-lives of around 17 h for the 6, 12, and 20 mg doses. Plasma drug exposure and Cmax increased in proportion to dose. Only 0.02% of RTI-336 excreted was unchanged in urine. Active metabolites UC-M5, UC-M8, and UC-M2 were measurable in plasma and urine, with plasma Cmax of UC-M5 and UC-M8 exceeding that of RTI-336. Three AE possibly were related to RTI-336 and resolved with discontinuation; the one serious AE was unrelated to RTI-336. 2 participants had transient and mild serum total bilirubin elevations (< 1.5 x upper limit of normal) at day 3 post-dose which resolved by day 8 post-dose. Conclusion: All doses including the highest (20 mg) showed excellent safety and tolerability, and further studies in humans are warranted.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] A First-In-Human, Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ketamine in Healthy Volunteers
    Silman, Daniel
    Gadelrab, Romayne
    Qureshi, Mutahira
    Stein, Hans
    Mehta, Mitul
    Carmelline, Pietro
    Young, Allan
    Reilly, Carmel
    Duncan, Graeme
    Juruena, Mario
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 155 - 155
  • [42] A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers
    Bani, M
    Colantoni, A
    Guillaume, M
    Macchi, F
    Moroni, G
    Persiani, S
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 50 (04) : 338 - 349
  • [43] A randomized, double-blind, placebo-controlled trial to evaluate the safety and tolerability of two doses of divalproex sodium in outpatients with probable Alzheimer's disease
    Profenno, L
    Jakimovich, L
    Holt, C
    Porsteinsson, A
    Tariot, P
    INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 351 - 352
  • [44] SAFETY AND TOLERABILITY OF ZS-9 IN A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN PATIENTS WITH HYPERKALAEMIA
    Packham, David K.
    Rasmussen, Henrik S.
    Lavin, Philip T.
    Yang, Alex
    Qunibi, Wajeh Y.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 184 - 184
  • [45] Safety and Tolerability of Dexpramipexole for the Treatment of ALS: Results from the Randomized, Double-Blind, Placebo-Controlled Trial, EMPOWER
    Van den Berg, Leonard
    Cudkowicz, Merit
    Shefner, Jeremy
    Mitsumoto, Hiroshi
    Mora, Jesus
    Ludolph, Albert
    Hardiman, Orla
    Ingersoll, Evan
    Archibald, Donald
    Li, Xiaoxi
    Dong, Yingwen
    Kerr, Douglas
    Farwell, Wildon
    NEUROLOGY, 2013, 80
  • [46] SAFETY AND TOLERABILITY OF BRIVARACETAM AS ADJUNCTIVE TREATMENT IN ADULTS WITH REFRACTORY EPILEPSY: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Kwan, P.
    Johnson, M. E.
    Falter, U.
    Pietteur, V. B.
    Brodsky, A. C.
    von Rosenstiel, P.
    EPILEPSIA, 2009, 50 : 107 - 108
  • [47] Safety and tolerability of Korean Red Ginseng in healthy adults: a multicenter, double-blind, randomized, placebo-controlled trial
    Song, Sang-Wook
    Kim, Ha-Na
    Shim, Jae-Yong
    Yoo, Byeong-Yeon
    Kim, Dae-Hyun
    Lee, Sang-Hyun
    Park, Joo-Sung
    Kim, Moon-Jong
    Yoo, Jun-Hyun
    Cho, BeLong
    Kang, Hee-Cheol
    Kim, Kwang-Min
    Kim, Sung-Soo
    Kim, Kyung-Soo
    JOURNAL OF GINSENG RESEARCH, 2018, 42 (04) : 571 - 576
  • [48] Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH
    Denis, L
    Pagano, F
    Nonis, A
    Robertson, C
    Romano, P
    Boyle, P
    PROSTATE, 1998, 37 (04): : 246 - 252
  • [49] Safety, Tolerability, and Pharmacokinetics of Single Escalating Doses of Oral Semaglutide in Healthy Male Subjects
    Baekdal, Tine A.
    Blicher, Thalia M.
    Donsmark, Morten
    Sondergaard, Flemming L.
    DIABETES, 2017, 66 : A318 - A318
  • [50] Safety and Tolerability, Dose-Escalating, Double-Blind Trial of Oral Mannitol in Parkinson's Disease
    Linetsky, Eduard
    Abd Elhadi, Suaad
    Bauer, Max
    Gallant, Akiva
    Namnah, Montaser
    Weiss, Sagit
    Segal, Daniel
    Sharon, Ronit
    Arkadir, David
    FRONTIERS IN NEUROLOGY, 2022, 12